Latest news with #SathgenTherapeutics
Fibre2Fashion
6 days ago
- Business
- Fibre2Fashion
Godavari Biorefineries gets Chinese patent for cancer molecule
Godavari Biorefineries Limited (BSE: 544279 | NSE: GODAVARIB), through its clinical-stage biotech division Sathgen Therapeutics, has been granted a patent by the China National Intellectual Property Administration (CNIPA), China's patent and trademark office for its novel anti-cancer molecule - HYDROXY-1,4-NAPHTHALENEDIONE. This patent covers a novel class of compounds that have exhibited strong inhibitory effects on cancer and cancer stem cells in vitro studies. These compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer. 'Our focus on original, high-quality science continues to guide our journey beyond green chemistry into life sciences,' said Dr Sangeeta Srivastava, Executive Director, Godavari Biorefineries Limited. 'This Chinese patent reinforces the promise of our lead molecule and the vital work being done by our team at Sathgen Therapeutics to develop innovative therapies for some of the most pressing medical needs worldwide.' Godavari Biorefineries has established a global presence, exporting to over 20 countries and maintaining strong linkages with international research and development networks. The company's clinical-stage biotech division, Sathgen Therapeutics, is at the forefront of advancing novel cancer and antiviral therapies. With a lead molecule undergoing clinical trials and global patent protection, GBL is deepening its focus in translational research that addresses some of the world's most urgent health challenges. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged. Godavari Biorefineries' biotech arm, Sathgen Therapeutics, has secured a Chinese patent for its anti-cancer molecule Hydroxy-1,4-Naphthalenedione. The compound shows strong in vitro efficacy against cancer and cancer stem cells. GBL continues to expand globally, focusing on innovative cancer and antiviral therapies through advanced translational research. ALCHEMPro News Desk (HU)
Mint
22-07-2025
- Business
- Mint
Godavari Biorefineries share price hits upper circuit despite rising 30% in one month; here's why
Small-cap stock Godavari Biorefineries' shares hit their upper circuit on Tuesday, 22 July 2025, after the company secured a patent for its 'novel anti-cancer molecule' from China's patent and trademark office, according to an exchange filing. 'Godavari Biorefineries Ltd, through its clinical-stage biotech division Sathgen Therapeutics, has been granted a patent by the China National Intellectual Property Administration (CNIPA), China's patent and trademark office, for its novel anti-cancer molecule — HYDROXY-1,4-NAPHTHALENEDIONE,' the company informed the BSE through the filing. Godavari Biorefineries is a major producer of ethanol and ethanol-based chemicals in India. The company manufactures bio-based chemicals, sugar, rectified spirits, ethanol, other grades of alcohol and power, according to the official website. (This is a developing story. Please check back for updates.) Read all stories by Anubhav Mukherjee Disclaimer: This story is for educational purposes only. The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
&w=3840&q=100)
Business Standard
22-07-2025
- Business
- Business Standard
Godavari Biorefineries stock jumps 5% on Chinese patent for cancer drug
Godavari Biorefineries share price today: Shares of Godavari Biorefineries surged 5 per cent on Tuesday, July 22, 2025, recording an intraday high of ₹327.43 per share. At 01:35 PM, shares of Godavari Biorefineries were trading at the day's highest level on the National Stock Exchange. In comparison, NSE Nifty was trading largely flat at 25,082.45, down by 8 points. The total market capitalisation of the company stood at ₹1,675.66 crore. So far this calendar year, the shares of the company have remained flat, albeit in the red territory, down by just over 1 per cent. Why were Godavari Biorefineries' shares buzzing in trade? The buying on the counter came after the company announced in a latest exchange filing that its clinical-stage biotech division, Sathgen Therapeutics, was granted a patent by the China National Intellectual Property Administration (CNIPA) for its novel anticancer molecule. The patent covers a novel class of compounds that have shown strong inhibitory effects on cancer and cancer stem cells in vitro studies. These compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer, as per the exchange filing. "Our focus on original, high-quality science continues to guide our journey beyond green chemistry into life sciences,' said Dr. Sangeeta Srivastava, executive director, Godavari Biorefineries. 'This Chinese patent reinforces the promise of our lead molecule and the vital work being done by our team at Sathgen Therapeutics to develop innovative therapies for some of the most pressing medical needs worldwide," she added. Godavari Biorefineries already has an established presence on the global front. Its biotech division, Sathgen Therapeutics, is actively involved in the development of novel cancer and antiviral therapies. It is also worth mentioning that just earlier this month, the company was granted a patent in Europe for its novel anticancer molecule. About Godavari Biorefineries Godavari Biorefineries was originally incorporated as 'Godavari Investment and Finance Corporation Ltd.' in Mumbai on January 12, 1956. The name of the company was changed on November 10, 2006, as 'Godavari Biorefineries'. The company is involved in the manufacturing of ethanol-based chemicals in India and has one of the largest integrated bio-refineries in the country in terms of installed capacity.
